Evaluating a Mendelian Risk Prediction Model That Aggregates Across Genes and Cancers
Genetic Epidemiology · 2026-04 · 50 (3)
DOI: 10.1002/gepi.70038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetic Epidemiology, online erschienen am 07.03.2026. Verfasst von Jane W Liang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Neoplasms, Genes, Neoplasm, Genetic Predisposition to Disease. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Using principles of Mendelian genetics, probability theory, and mutation‐specific knowledge, Mendelian risk prediction models identify those at high risk of carrying a heritable cancer susceptibility variant and assess future risk of cancer. Our previously‐validated Fam3PRO model is a generalizable and computationally efficient Mendelian risk prediction framework that incorporates an arbitrary number of gene‐cancer associations. In practice, from a model training perspective, there may be uncertainty in estimating the population‐level model parameters necessary for rare gene‐cancer associations. From a clinical perspective, it may be infeasible to obtain a detailed patient family history for many cancers. Motivated by the context of pre‐screening for germline testing of a broad hereditary cancer gene panel, we propose a Mendelian model that aggregates information across genes and cancers, reducing patient burden and bypassing the need for robust parameter estimation for rare genes and syndromes. We evaluated this aggregate model through simulations and applied it to two independent clinical cohorts. We show that when the clinical goal is to assess patient risk of carrying a pathogenic variant for any cancer susceptibility gene, the aggregate model can give results comparable to a Mendelian model that considers many genes and cancers individually, while greatly simplifying model assumptions and user input.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Division of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
- Center of Precision Medicine, City of Hope, Duarte, California, USA.
- Cancer Center Genetics Program, Massachusetts General Hospital, Boston, Massachusetts, USA.
- School of Health & Rehabilitation Sciences, MGH Institute of Health Professions, Boston, Massachusetts, USA.
ORCID-Profile: Jane W Liang
Förderung
- NCATS NIH HHS
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Liang, J. W., Idos, G. E., Hong, C., Shannon, K. M., Bear, L. M., Pichardo, J. M., Guan, Z., McCarthy, A. M., Ford, J. M., Kurian, A. W., Gruber, S. B., Braun, D., & Parmigiani, G. (2026). Evaluating a Mendelian Risk Prediction Model That Aggregates Across Genes and Cancers. Genetic Epidemiology, 50(3). https://doi.org/10.1002/gepi.70038
Vancouver
Liang JW, Idos GE, Hong C, Shannon KM, Bear LM, Pichardo JM, et al. Evaluating a Mendelian Risk Prediction Model That Aggregates Across Genes and Cancers. Genetic Epidemiology. 2026;50(3). doi:10.1002/gepi.70038
BibTeX
@article{Liang2026,
author = {Liang, Jane W and Idos, Gregory E and Hong, Christine and Shannon, Kristen M and Bear, Lauren M and Pichardo, Jennifer Morales and Guan, Zoe and McCarthy, Anne Marie and Ford, James M and Kurian, Allison W and Gruber, Stephen B and Braun, Danielle and Parmigiani, Giovanni},
title = {Evaluating a Mendelian Risk Prediction Model That Aggregates Across Genes and Cancers},
journal = {Genetic Epidemiology},
year = {2026},
volume = {50},
number = {3},
doi = {10.1002/gepi.70038}
}
EUVIMED